Hospital
Samaritan Regional Health System
Samaritan Regional Health System was paid $10.39M by Medicaid between Jan 2018 and Dec 2024, across 206 billing codes. Its largest line is 99283, emergency room visit (moderate) — 21% of everything it billed.
33Billing provider infoSAMARITAN REGIONAL HEALTH SYSTEM
ASHLAND, OH 44805
ASHLAND, OH 44805
33aNPI1902882939assigned 12/21/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$10.39M
24GClaims268,324
24DCodes billed206
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Ohio
Rank by total paid#77 of 101
Median peer was paid$22.32M
This provider vs. median0.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official SCHILLERO, ANTHONY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 30,225 | $919K | |
| 2019 | 25,204 | $774K | |
| 2020 | 20,596 | $868K | |
| 2021 | 29,418 | $1.10M | |
| 2022 | 21,192 | $955K | |
| 2023 | 81,237 | $3.32M | |
| 2024incomplete | 60,452 | $2.45M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 21% | 20,002 | 18,294 | $2.23M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 10,878 | 9,518 | $1.34M |
| 96361 | Intravenous infusion, hydration; each additional hour | 11% | 4,710 | 3,752 | $1.12M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 7.4% | 12,931 | 12,003 | $769K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.0% | 6,754 | 5,834 | $726K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 5.1% | 6,612 | 2,160 | $534K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.0% | 1,791 | 1,387 | $415K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.6% | 1,425 | 1,210 | $377K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 2.9% | 3,715 | 1,139 | $300K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 2.3% | 3,528 | 3,245 | $242K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.8% | 2,815 | 722 | $192K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.8% | 1,499 | 952 | $188K |
194 more codes
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.6% | 859 | $162K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.3% | 548 | $133K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 379 | $94K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 2,021 | $89K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 391 | $88K |
| 80053 | Comprehensive metabolic panel | <1% | 11,978 | $87K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 365 | $87K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 898 | $62K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,156 | $59K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 7,863 | $55K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 119 | $49K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 2,124 | $49K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,621 | $49K |
| 97161 | <1% | 926 | $47K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 405 | $45K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 269 | $42K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 703 | $36K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 186 | $34K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 309 | $32K |
| 74018 | <1% | 647 | $28K | |
| G0378 | Hospital observation service, per hour | <1% | 476 | $26K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 235 | $26K |
| 36415 | Collection of venous blood by venipuncture | <1% | 17,914 | $25K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 20,428 | $23K |
| 87428 | <1% | 762 | $20K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 378 | $20K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 1,420 | $19K |
| 76770 | <1% | 112 | $19K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,566 | $18K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 406 | $17K |
| 73030 | <1% | 500 | $16K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 130 | $15K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 953 | $14K |
| 73630 | <1% | 580 | $14K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 8,868 | $14K |
| 73610 | <1% | 431 | $12K | |
| 97113 | <1% | 113 | $11K | |
| 84484 | <1% | 5,357 | $11K | |
| 73130 | <1% | 424 | $11K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 405 | $11K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 353 | $11K |
| 94060 | <1% | 73 | $11K | |
| 85027 | <1% | 1,714 | $10K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 892 | $10K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 703 | $10K |
| 72100 | <1% | 294 | $9K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 553 | $8K |
| 80076 | <1% | 1,657 | $8K | |
| 73564 | <1% | 242 | $8K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 712 | $8K |
| 71045 | Radiologic examination, chest; single view | <1% | 4,175 | $8K |
| 93971 | <1% | 92 | $7K | |
| 88174 | <1% | 576 | $7K | |
| 96367 | <1% | 183 | $7K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 468 | $7K |
| 76536 | <1% | 75 | $7K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,769 | $7K |
| 80061 | Lipid panel | <1% | 555 | $7K |
| 73110 | <1% | 234 | $6K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,588 | $6K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 33 | $6K |
| 87631 | <1% | 118 | $6K | |
| 71250 | <1% | 62 | $5K | |
| 82607 | <1% | 184 | $5K | |
| 94200 | <1% | 76 | $5K | |
| 94726 | <1% | 75 | $5K | |
| 86850 | <1% | 166 | $5K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 339 | $5K |
| 94729 | <1% | 76 | $4K | |
| 73562 | <1% | 62 | $3K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 6,190 | $3K |
| 83605 | <1% | 3,145 | $3K | |
| 73502 | <1% | 154 | $3K | |
| 86900 | <1% | 176 | $3K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 13 | $3K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 26 | $3K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 23 | $3K |
| 76000 | <1% | 19 | $3K | |
| 93017 | <1% | 31 | $3K | |
| 76642 | <1% | 26 | $3K | |
| 76830 | Ultrasound, transvaginal | <1% | 122 | $2K |
| 86780 | <1% | 79 | $2K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 86 | $2K |
| J1610 | Injection, glucagon hydrochloride, per 1 mg | <1% | 16 | $2K |
| 59025 | Fetal non-stress test | <1% | 18 | $2K |
| 72110 | <1% | 30 | $2K | |
| 81003 | <1% | 3,161 | $1K | |
| 81001 | <1% | 6,728 | $1K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 53 | $1K |
| 94664 | <1% | 785 | $1K | |
| 82947 | <1% | 1,198 | $1K | |
| 80320 | <1% | 70 | $1K | |
| 86901 | <1% | 175 | $1K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,210 | $1K |
| 97165 | <1% | 12 | $1K | |
| 81002 | <1% | 241 | $1K | |
| 96376 | <1% | 578 | $1K | |
| 82728 | <1% | 52 | $1K | |
| 83540 | <1% | 77 | $1K | |
| 95012 | <1% | 12 | $1K | |
| 83735 | <1% | 1,418 | $988.31 | |
| 99152 | <1% | 411 | $946.12 | |
| 83690 | <1% | 3,566 | $894.12 | |
| 82077 | <1% | 693 | $823.88 | |
| 83550 | <1% | 65 | $820.08 | |
| 85610 | <1% | 1,571 | $806.88 | |
| 86762 | <1% | 27 | $770.52 | |
| 70486 | <1% | 15 | $750.55 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 28 | $731.57 |
| 90715 | <1% | 64 | $683.81 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 656 | $635.24 |
| 87340 | <1% | 38 | $597.31 | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 13 | $577.60 |
| 93242 | <1% | 13 | $483.29 | |
| 84702 | <1% | 492 | $479.50 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,399 | $460.90 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 6,315 | $418.15 |
| 87081 | <1% | 13 | $416.79 | |
| 72040 | <1% | 15 | $387.74 | |
| 86803 | <1% | 12 | $353.78 | |
| 80143 | <1% | 370 | $348.82 | |
| 82805 | <1% | 14 | $341.47 | |
| 81025 | <1% | 1,243 | $340.54 | |
| 36591 | <1% | 18 | $321.57 | |
| 85379 | <1% | 842 | $307.32 | |
| 82746 | <1% | 25 | $306.80 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 59 | $302.85 |
| J3490 | Unclassified drugs | <1% | 687 | $276.04 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 28 | $256.09 |
| 94762 | <1% | 42 | $232.79 | |
| 85730 | <1% | 631 | $211.60 | |
| 87186 | <1% | 206 | $208.00 | |
| 87634 | <1% | 131 | $204.51 | |
| 51798 | <1% | 38 | $197.23 | |
| 87075 | <1% | 242 | $195.06 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 667 | $192.34 |
| 84439 | <1% | 12 | $187.43 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 134 | $175.86 |
| 87040 | <1% | 435 | $163.47 | |
| 80179 | <1% | 362 | $162.05 | |
| 01936 | <1% | 146 | $161.77 | |
| 84703 | <1% | 567 | $147.64 | |
| 83880 | <1% | 543 | $143.94 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 610 | $118.67 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 126 | $114.61 |
| 86140 | <1% | 38 | $110.80 | |
| 82248 | <1% | 299 | $109.81 | |
| 80329 | <1% | 12 | $98.48 | |
| 87077 | <1% | 132 | $98.30 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,239 | $92.42 |
| 82950 | <1% | 14 | $84.46 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 85 | $81.91 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 47 | $76.66 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 340 | $71.94 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 309 | $69.75 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 307 | $46.72 |
| 82948 | <1% | 13 | $42.17 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,110 | $39.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 493 | $27.99 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 754 | $20.29 |
| 82550 | <1% | 81 | $17.87 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 442 | $14.27 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 830 | $13.98 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,128 | $13.69 |
| J2704 | Injection, propofol, 10 mg | <1% | 1,112 | $8.38 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,166 | $8.17 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 152 | $5.07 |
| 36416 | <1% | 187 | $5.00 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 55 | $3.89 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 122 | $3.45 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 16 | $3.18 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 555 | $2.63 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 66 | $1.09 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 85 | $0.63 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 33 | $0.18 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,376 | $0.17 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 356 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 20 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 35 | $0.00 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 160 | $0.00 |
| 0753T | 0% | 30 | $0.00 | |
| 94760 | 0% | 191 | $0.00 | |
| 94761 | 0% | 556 | $0.00 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 182 | $0.00 |
| A9270 | Non-covered item or service | 0% | 897 | $0.00 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 312 | $0.00 |
| 99153 | Mod sedat endo service >5yrs | 0% | 69 | $0.00 |
| A9698 | Non-radioactive contrast imaging material, not otherwise classified, per study | 0% | 139 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 81 | $0.00 |
| 82150 | 0% | 29 | $0.00 | |
| 76377 | 0% | 46 | $0.00 | |
| 74022 | 0% | 12 | $0.00 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | 0% | 99 | $0.00 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 0% | 20 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSCHILLERO, ANTHONY (DIRECTOR, FP&A)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.